Junji Furuse

2002–2025 年に発表

142
論文数
23,290
被引用数
74
h 指数
136
i10 指数

被引用数

Junji Furuse の年別被引用数1939 年: 被引用 1 件2003 年: 被引用 1 件2005 年: 被引用 4 件2006 年: 被引用 9 件2007 年: 被引用 11 件2008 年: 被引用 22 件2009 年: 被引用 40 件2010 年: 被引用 29 件2011 年: 被引用 34 件2012 年: 被引用 71 件2013 年: 被引用 72 件2014 年: 被引用 86 件2015 年: 被引用 131 件2016 年: 被引用 107 件2017 年: 被引用 117 件2018 年: 被引用 125 件2019 年: 被引用 602 件2020 年: 被引用 862 件2021 年: 被引用 931 件2022 年: 被引用 1,026 件2023 年: 被引用 969 件2024 年: 被引用 1,671 件2025 年: 被引用 751 件2026 年: 被引用 10 件1940〜2002 年は被引用が無いため表示していません2004 年は被引用が無いため表示していません

引用元

国・地域

この著者を引用した国・地域の世界地図中国: 引用元論文 1,695 件、この内訳の 17.3%アメリカ合衆国: 引用元論文 1,605 件、この内訳の 16.4%日本: 引用元論文 1,139 件、この内訳の 11.6%イタリア: 引用元論文 656 件、この内訳の 6.7%ドイツ: 引用元論文 527 件、この内訳の 5.4%イギリス: 引用元論文 456 件、この内訳の 4.7%韓国: 引用元論文 385 件、この内訳の 3.9%フランス: 引用元論文 374 件、この内訳の 3.8%スペイン: 引用元論文 311 件、この内訳の 3.2%台湾: 引用元論文 212 件、この内訳の 2.2%カナダ: 引用元論文 205 件、この内訳の 2.1%オランダ: 引用元論文 147 件、この内訳の 1.5%
0%17.3%その他 21.2%

分野

  • Medicine81.4%
  • Biochemistry, Genetics and Molecular Biology14.1%
  • Immunology and Microbiology2.6%
  • Engineering0.4%
  • Neuroscience0.3%
  • Materials Science0.2%
  • その他1%

トピック

  • Hepatocellular Carcinoma Treatment and Prognosis10.9%
  • Cholangiocarcinoma and Gallbladder Cancer Studies9%
  • Cancer Immunotherapy and Biomarkers6.9%
  • Pancreatic and Hepatic Oncology Research6.9%
  • Gallbladder and Bile Duct Disorders3.3%
  • Cancer Mechanisms and Therapy2.8%
  • その他60.2%

共著者

全論文

検索で開く
  1. Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Bruno Sangro - NEJM Evidence 2022 被引用: 1,432

  2. Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , - The Lancet Oncology 2021 被引用: 1,097

  3. Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Yuxian Bai, Olga Barajas, Susan E. Bates, Stephen Begbie, Irit Ben‐Aharon, Nina Beri, Marie‐Luise Berres, Jean‐Frédéric Blanc, Ivan Borbath, Robert Bordonaro, Mohamed Bouattour, Giovanni Brandi, Adam M. Burgoyne, Kritiya Butthongkomvong, Marcos Pedro Guedes Camandaroba, Ke Cao, Marcela Carballido, Marcela Carballido, Jen‐Shi Chen, Ming‐Huang Chen, Ming-Huang Chen, Ashley Cheng, Tai‐Jan Chiu, Hye Jin Choi, Hong Jae Chon, Joëlle Collignon, Antonio Cubillo Gracián, S. Lindsey Davis, Ricardo Saraiva de Carvalho, D.J.A. de Groot, Anne Demols, Judith de Vos, Maria Diab, Jacob C. Easaw, Martin Eatock, Julien Edeline, Rawad Elias, Fredericus Eskens, Alfredo Falcone, Plinio Fernández, Richard S. Finn, Fábio Franke, Masayuki Furukawa, Junji Furuse, Olumide B. Gbolahan, Karen Geboes, Keri-Lee Geneser, Zhimin Geng, Ravit Geva, Roopinder Gillmore, Thorsten Oliver Goetze, Hongfeng Gou, Julieta Grasselli, Shanzhi Gu, Mahmut Gümüş, Nadia Haj Mohammad, Chunyi Hao, Hakan Harputluoğlu, Hassan Hatoum, Volker Heinemann, Wang Kwong Ho, Chiun Hsu, Ayala Hubert, Jun‐Eul Hwang, Mevlüde İnanç, Soledad Iseas, Vaishnavi Jeyasingam, Paula Jiménez Fonseca, Warren Joubert, Jitlada Juengsamarn ほか 116 名 - The Lancet 2023 被引用: 1,025

  4. Futibatinib for FGFR2 -Rearranged Intrahepatic Cholangiocarcinoma

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2023 被引用: 541

  5. Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Jean–Luc Van Laethem, Eric Van Cutsem, Scott Berry, Mark Vincent, Bettina Müller, Felipe Rey, Ángela R. Zambrano, Joaquín Guerra, Merete Krogh, Lene Bæksgaard, Mette Yilmaz, Anneli Elme, Andrus Magi, Päivi Auvinen, Tuomo Alanko, Markus Moehler, Volker Kunzmann, Thomas Seufferlein, Peter Thuss-Patience, Eray Goekkurt, Thomas Hoehler, Georg Martin Haag, Salah‐Eddin Al‐Batran, Hugo R. Castro, Karla Alejandra Lopez, Mynor Aguilar Vasquez, Mario Sandoval, Ka On Lam, Sinéad Cuffe, Cathy Kelly, Ravit Geva, Einat Shacham‐Shmueli, Ayala Hubert, Alex Beny, Baruch Brenner, Giuseppe Aprile, Alfredo Falcone, Evaristo Maiello, Rodolfo Passalacqua, Vincenzo Montesarchio, Hiroki Hara, Keisho Chìn, Tomohiro Nishina, Yoshito Komatsu, Nozumo Machida, Shuichi Hironaka, Taroh Satoh, Takao Tamura, Naotaoshi Sugimoto, Haruhiko Cho, Yashushi Omuro, Ken Kato, Masahiro Goto, Ichinosuke Hyodo, Kazuhiro Yoshida, Hideo Baba, Taito Esaki, Junji Furuse, Wan Zamaniah Wan Mohammed, Carlos Hernández Hernández, Juan Casas Garcia, Adriana Dominguez Andrade, Katriona Clarke, Geir Olav Hjortland, Nils Glenjen, Tomasz Kubiatowski, Jassem Jacek, Marek Z. Wojtukiewicz, Sergey Lazarev, Yuri Lancukhay ほか 58 名 - The Lancet 2018 被引用: 1,316

  6. Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , - Gut 2019 被引用: 723

  7. Association of inflammatory biomarkers with clinical outcomes in nivolumab-treated patients with advanced hepatocellular carcinoma

    著者: , , , , , , , , , , , , , , - Journal of Hepatology 2020 被引用: 421

  8. Phase 3 randomized, open-label, multicenter study of tremelimumab (T) and durvalumab (D) as first-line therapy in patients (pts) with unresectable hepatocellular carcinoma (uHCC): HIMALAYA.

    著者: , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2022 被引用: 400

  9. Clinical utility of circulating tumor DNA sequencing in advanced gastrointestinal cancer: SCRUM-Japan GI-SCREEN and GOZILA studies

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Takeharu Yamanaka, Miki Izumi, Yasutoshi Sakamoto, Hiroko Ichiki, Masayuki Hata, Riu Yamashita, Atsushi Ohtsu, Justin I. Odegaard, Takayuki Yoshino - Nature Medicine 2020 被引用: 366

  10. Clinical Practice Guidelines for Hepatocellular Carcinoma: The Japan Society of Hepatology 2021 version (5th JSH‐HCC Guidelines)

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , - Hepatology Research 2023 被引用: 269

  11. Adjuvant S-1 compared with observation in resected biliary tract cancer (JCOG1202, ASCOT): a multicentre, open-label, randomised, controlled, phase 3 trial

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Takuji Okusaka, Yoshihiro Sakamoto, Yasushi Kojima, Ryota Higuchi, Naoki Sasahira, Keiji Sano, Toshio Nakagohri, Yu Sunakawa, Soichiro Morinaga, Yusuke Kumamoto, Kazuya Sugimori, Tatsuya Nomura, Kazuto Shibuya, Isamu Makino, Kentaro Yamazaki, Nobumasa Mizuno, Ken Kamata, Hiroshi Wada, Kunihito Gotoh, Mitsugu Sekimoto, Tetsuo Ajiki, Ikuo Nakamura, Ikuya Miki, Hiroaki Nagano, Koji Ohta, Takehiro Okabayashi, Masayuki Furukawa, Nao Fujimori - The Lancet 2023 被引用: 232

  12. Final Results of TACTICS: A Randomized, Prospective Trial Comparing Transarterial Chemoembolization Plus Sorafenib to Transarterial Chemoembolization Alone in Patients with Unresectable Hepatocellular Carcinoma

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , - Liver Cancer 2022 被引用: 128

  13. Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan

    著者: , , , , , , , , , , , , , , - British Journal of Cancer 2010 被引用: 752

  14. Randomized phase II/III trial of neoadjuvant chemotherapy with gemcitabine and S-1 versus upfront surgery for resectable pancreatic cancer (Prep-02/JSAP05)

    著者: , , , , , , , , , , , , - Japanese Journal of Clinical Oncology 2018 被引用: 534

  15. Combination gemcitabine plus S-1 versus gemcitabine plus cisplatin for advanced/recurrent biliary tract cancer: the FUGA-BT (JCOG1113) randomized phase III clinical trial

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Naoya Kato, Kazuhiko Shioji, Kyoko Shimizu, Toshio Nakagohri, Ken Kamata, Hiroshi Ishii, Junji Furuse - Annals of Oncology 2019 被引用: 334

  16. Trastuzumab deruxtecan (T-DXd; DS-8201) in patients (pts) with HER2-expressing unresectable or recurrent biliary tract cancer (BTC): An investigator-initiated multicenter phase 2 study (HERB trial).

    著者: , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2022 被引用: 107

  17. Nivolumab alone or in combination with cisplatin plus gemcitabine in Japanese patients with unresectable or recurrent biliary tract cancer: a non-randomised, multicentre, open-label, phase 1 study

    著者: , , , , , , , , , , , - ˜The œLancet. Gastroenterology & hepatology 2019 被引用: 332

  18. A Phase 2, Prospective, Multicenter, Single-Arm Trial of Transarterial Chemoembolization Therapy in Combination Strategy with Lenvatinib in Patients with Unresectable Intermediate-Stage Hepatocellular Carcinoma: TACTICS-L Trial

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , - Liver Cancer 2023 被引用: 94

  19. FIGHT-302: first-line pemigatinib vs gemcitabine plus cisplatin for advanced cholangiocarcinoma with FGFR2 rearrangements

    著者: , , , , , , , , , , , , , , , , , - Future Oncology 2020 被引用: 165

  20. Observational registry of sorafenib use in clinical practice across Child-Pugh subgroups: The GIDEON study

    著者: , , , , , , , , , , , , , , , , , - Journal of Hepatology 2016 被引用: 385

  21. The Incidence and Epidemiology of Hepatocellular Carcinoma: A Global and Regional Perspective

    著者: , , , - The Oncologist 2010 被引用: 977

  22. Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma

    著者: , , , , , , , , , , , , , , , , , , , , , - European Journal of Cancer 2011 被引用: 573

  23. Chemotherapy for hepatocellular carcinoma: current status and future perspectives

    著者: , , , , , - Japanese Journal of Clinical Oncology 2017 被引用: 274

  24. Effect of Everolimus on Survival in Advanced Hepatocellular Carcinoma After Failure of Sorafenib

    著者: , , , , , , , , , , , , , , , , , , , - JAMA 2014 被引用: 569